Gilead Sciences | GILD - Ordinary Share Capital


Gilead Sciences reported $1.24B in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 541M 1000K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
United Therapeutics USD 42.68M 521K Jun/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026